Insider Trading Alert - BCR, CBG And FANG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 26, 2014, 172 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $41.00 to $204,930,000.00.

Highlighted Stocks Traded by Insiders:

C.R. Bard (BCR) - FREE Research Report

Ring Timothy M who is Chairman and CEO at C.R. Bard sold 6,760 shares at $142.85 on Feb. 26, 2014. Following this transaction, the Chairman and CEO owned 172,216 shares meaning that the stake was reduced by 3.78% with the 6,760-share transaction.

The shares most recently traded at $143.85, up $1.00, or 0.7% since the insider transaction. Historical insider transactions for C.R. Bard go as follows:

  • 4-Week # shares sold: 31,766
  • 12-Week # shares sold: 63,625
  • 24-Week # shares sold: 74,922

The average volume for C.R. Bard has been 648,000 shares per day over the past 30 days. C.R. Bard has a market cap of $11.0 billion and is part of the health care sector and health services industry. Shares are up 6.79% year-to-date as of the close of trading on Wednesday.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The stock currently has a dividend yield of 0.59%. The company has a P/E ratio of 16.9. Currently there are 4 analysts that rate C.R. Bard a buy, 1 analyst rates it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BCR - FREE

TheStreet Quant Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full C.R. Bard Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CBRE Group (CBG) - FREE Research Report

Lafitte Michael J who is Chief Operating Officer at CBRE Group sold 12,500 shares at $27.75 on Feb. 26, 2014. Following this transaction, the Chief Operating Officer owned 279,297 shares meaning that the stake was reduced by 4.28% with the 12,500-share transaction.

The shares most recently traded at $27.74, down $0.01, or 0.05% since the insider transaction. Historical insider transactions for CBRE Group go as follows:

  • 4-Week # shares sold: 66,913
  • 12-Week # shares sold: 66,913
  • 24-Week # shares sold: 66,913

The average volume for CBRE Group has been 2.4 million shares per day over the past 30 days. CBRE Group has a market cap of $9.2 billion and is part of the financial sector and real estate industry. Shares are up 5.06% year-to-date as of the close of trading on Wednesday.

CBRE Group, Inc. operates as a commercial real estate services and investment company. The company's segments include Americas; Europe, Middle East and Africa (EMEA); Asia Pacific; Global Investment Management; and Development Services. The company has a P/E ratio of 19.5. Currently there are 4 analysts that rate CBRE Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBG - FREE

TheStreet Quant Ratings rates CBRE Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full CBRE Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Diamondback Energy (FANG) - FREE Research Report

Wexford Capital Lp who is 10% Owner at Diamondback Energy sold 62,100 shares at $66.66 on Feb. 26, 2014. Following this transaction, the 10% Owner owned 10.6 million shares meaning that the stake was reduced by 0.58% with the 62,100-share transaction.

The shares most recently traded at $64.01, down $2.65, or 4.13% since the insider transaction. Historical insider transactions for Diamondback Energy go as follows:

  • 4-Week # shares sold: 705,009
  • 12-Week # shares sold: 3.0 million
  • 24-Week # shares sold: 3.3 million

The average volume for Diamondback Energy has been 899,100 shares per day over the past 30 days. Diamondback Energy has a market cap of $3.0 billion and is part of the basic materials sector and energy industry. Shares are up 22.05% year-to-date as of the close of trading on Wednesday.

Diamondback Energy, Inc., together with its subsidiaries, focuses on the acquisition, development, exploration, and exploitation of onshore oil and natural gas reserves in the Permian Basin in West Texas. The company has a P/E ratio of 49.4. Currently there are 13 analysts that rate Diamondback Energy a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FANG - FREE

TheStreet Quant Ratings rates Diamondback Energy as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Diamondback Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts

Good Medicine Makes for 3 Good Charts